Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyCommunity-Care Xolair Coverage Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentCommunity-CarePolicy N/A

    Xolair

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines initial and continuation coverage criteria, quantity limits, dosing tables, authorization periods, and applicable HCPCS code for omalizumab (Xolair) for severe asthma, chronic spontaneous urticaria, and IgE-mediated food allergy.

    Policy Summary
    PayerCommunity-Care
    PolicyXolair
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date
    Last ReviewDec 1, 2025
    Next Review Date
    Key ActionProviders must document baseline IgE level (>30 IU/mL where specified), diagnosis confirmation, prior treatment trials, prescriber specialty or consultation, prescriber attestation of adherence and non-concurrent targeted immunomodulator use, and patient weight for dosing.
    SourceLink
    POLICY UPDATE CHANGES

    No material changes

    3Covered Indications
    6m / 1yAuth periods (initial/cont)
    Dose-specific

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Quantity limits

    Coverage Summary

    This policy covers with criteria omalizumab (Xolair) for the treatment of severe asthma, chronic spontaneous urticaria, and IgE-mediated food allergy, defining initial and continuation approval requirements, dosing/quantity limits, and applicable HCPCS coding.

    Key thresholds and limits
    Baseline IgE requirement> 30 IU/mL
    Asthma exacerbations requirement≥ 2 exacerbations in past year (systemic steroids, ED visit, or hospitalization)
    Authorization periodsInitial: 6 months for asthma/CSU; Continuation: 1 year (IgE-mediated food allergy: 1 year)
    Quantity limits per 28 days — 75 mg2 injections per 28 days (75 mg = 0.5 mL)
    Quantity limits per 28 days — 150 mg2 injections per 28 days (150 mg = 1 mL)
    Quantity limits per 28 days — 300 mg1 injection per 28 days (300 mg = 2 mL)

    Initial Therapy Criteria

    Initial Approval - Severe asthma

    Covered when ALL of the following are met:

    ALL of the following

    • Age ≥ 6 years
    • Prescribed by, or in consultation with an allergist, pulmonologist, or immunologist
    • Diagnosis of severe asthma
    • Confirmation of diagnosis via skin test or RAST for specific allergy sensitivity
    • IgE Levels (> 30 IU/mL) prior to treatment, with baseline level provided> 30 IU/mL

    Continuation Therapy Criteria

    Continuation of Therapy - Severe asthma

    Covered when ALL of the following are met:

    Diagnosis of severe asthma at baseline
    Positive clinical response has been achieved
    Will not be used in combination with another targeted immunomodulator product used for asthma

    Continuation of Therapy - Chronic spontaneous urticaria

    Covered when ALL of the following are met:

    Diagnosis of chronic spontaneous urticaria

    Applicable Codes

    Applicable HCPCSHCPCS
    J2357Injection, omalizumab, 5 mg

    Provider Actions

    Prior Authorization

    Prior authorization required per clinical criteria

    Providers must submit documentation to meet clinical prior authorization criteria: baseline total IgE level (baseline IgE > 30 IU/mL where specified), confirmation of diagnosis by appropriate testing (skin test or RAST for asthma; skin prick or serum IgE for food allergy), history or trials of prior treatments (e.g., high‑dose H1 antihistamines for CSU; prior controller therapy and exacerbation/exacerbation history for asthma), documentation of prescriber specialty or documentation of consultation with an allergist/pulmonologist/dermatologist/immunologist as required, and prescriber attestation regarding adherence to controller therapies and that omalizumab will not be used concurrently with another targeted immunomodulator for asthma.

    • Affected code: J2357
    Documentation Required

    Weight required for approval and dosing

    Patient body weight must be provided for dosing determination and is required for approval. Dosing tables in the policy reference both baseline IgE and body weight to select the correct omalizumab dose.

    Background

    Omalizumab (Xolair) is an anti-IgE monoclonal antibody indicated in this policy for severe allergic asthma, chronic spontaneous urticaria, and certain IgE-mediated food allergy indications. Dosing and quantity limits are determined by baseline total serum IgE and patient body weight; the policy requires a baseline IgE level for initial dosing and documentation of patient weight for approval and dose selection.

    RAST: Radioallergosorbent test (specific IgE serum testing).

    CSU: Chronic spontaneous urticaria.

    Clinical Evidence

    The policy references clinical evidence for approved indications and describes coverage criteria and dosing tables, but no trial-level evidence metrics or individual study data were provided in the brief.

    Revision History

    2025-12-01Last reviewLatest

    Last review

    Policy Summary
    PayerCommunity-Care
    PolicyXolair
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date
    Last ReviewDec 1, 2025
    Next Review Date
    Key ActionProviders must document baseline IgE level (>30 IU/mL where specified), diagnosis confirmation, prior treatment trials, prescriber specialty or consultation, prescriber attestation of adherence and non-concurrent targeted immunomodulator use, and patient weight for dosing.
    SourceLink
    On This Page
    Coverage SummaryInitial Therapy CriteriaContinuation Therapy CriteriaApplicable CodesProvider ActionsBackgroundClinical EvidenceRevision History

    baseline IgE required

  1. History of ≥ 2 asthma exacerbations requiring systemic corticosteroids or ED visit or hospitalization for asthma within the past year despite adherent use of either an inhaled corticosteroid (ICS) with 1 additional asthma controller medication or maximally tolerated ICS/LABA combination product≥ 2 in past year
  2. Prescriber attestation

    • Patient adherence to controller medications
    • Will not be used in combination with another targeted immunomodulator product used for asthma
  3. Initial Approval - Chronic spontaneous urticaria

    Covered when ALL of the following are met:

    Age ≥ 12 years
    Prescribed by, or in consultation with, an allergist, dermatologist, or immunologist
    Diagnosis of chronic spontaneous urticaria
    Trial of high dose H1 antihistamines was ineffective, contraindicated, or not tolerated

    Initial Approval - IgE-mediated food allergy

    Covered when ALL of the following are met:

    Prescribed by, or in consultation with an allergist or immunologist
    Diagnosis of an IgE-mediated food allergy

    Diagnosis supported by either

    • Positive skin prick test
    • Positive serum IgE test

    One of the following

    • Diagnosis confirmed by a positive oral food challenge
    • History of anaphylaxis to the suspected food allergen
    Age ≥ 1 years
    Injectable epinephrine has previously been dispensed or will be prescribed along with omalizumab (Xolair)
    Omalizumab (Xolair) will be used in conjunction with strict adherence to allergen avoidance
    Will not be used in combination with peanut allergen powder (Palforzia)
    Documentation of pretreatment serum IgE levels to verify correct dosing

    baseline IgE required for dosing

    Documentation of positive clinical response

    Continuation of Therapy - IgE-mediated food allergy

    Covered when ALL of the following are met:

    Diagnosis of IgE-mediated food allergy
    Prescribed by, or in consultation with, an allergist or immunologist
    Will not be used in combination with peanut allergen powder (Palforzia)
    Injectable epinephrine has been dispensed

    Age-based continuation

    • Patient is age ≥ 18 years
    • If age 1-17 years, ONE of

      • Documentation of an off-treatment rechallenge confirming continued presence of IgE-mediated food allergy
      • Rechallenge is not appropriate for the patient at this time (rationale provided)
    • Dosing tables referenced in policy (see Appendix/Table sections for weight-and-IgE based dosing)
    Billing Rule

    Quantity limits per 28 days by dose

    Quantity limits are specified by dose and 28‑day period: 75 mg and 150 mg dose levels are limited to 2 injections per 28 days; the 300 mg dose is limited to 1 injection per 28 days.

    • Injection volume equivalents: 75 mg = 0.5 mL; 150 mg = 1 mL; 300 mg = 2 mL
    • Affected code: J2357
    Note

    Authorization durations

    Authorization durations in the policy: initial approvals for severe asthma and chronic spontaneous urticaria are allowed for 6 months; continuation approvals for those conditions are allowed for 1 year. Approvals for IgE‑mediated food allergy are allowed for 1 year.

    Documentation Required

    Epinephrine dispensing for food allergy

    For IgE‑mediated food allergy indications, injectable epinephrine must have previously been dispensed or will be prescribed along with omalizumab as a condition of coverage.